Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022

CEO Rob Davis said Merck is on track to fulfill its commitment in the coming days of delivering 3.1 million courses of its Covid treatment pill to the U.S.

from Health and Science https://ift.tt/R9wgBlZr2
https://ift.tt/QkKTRz4UJ
https://ift.tt/ym4f6QBYN